Join Growin Stock Community!

Bluejay diagnostics, inc.BJDX.US Overview

US StockHealthcare
(No presentation for BJDX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BJDX AI Insights

BJDX Overall Performance

BJDX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BJDX Recent Performance

-1.46%

Bluejay diagnostics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

BJDX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BJDX Key Information

BJDX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BJDX Profile

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Price of BJDX

BJDX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BJDX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-15.10
PE Ratio (TTM)
0.00
Forward PE
-
PS Ratio (TTM)
54.99
PB Ratio
0.40
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-15.10
PE Ratio (TTM)
0.00
Forward PE
-
PS Ratio (TTM)
54.99
PB Ratio
0.40
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is BJDX's latest earnings report released?

    The most recent financial report for Bluejay diagnostics, inc. (BJDX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BJDX's short-term business performance and financial health. For the latest updates on BJDX's earnings releases, visit this page regularly.

  • How much debt does BJDX have?

    As of the end of the reporting period, Bluejay diagnostics, inc. (BJDX) had total debt of 142.99K, with a debt ratio of 0.03. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BJDX have?

    At the end of the period, Bluejay diagnostics, inc. (BJDX) held Total Cash and Cash Equivalents of 3.08M, accounting for 0.63 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is BJDX's EPS continuing to grow?

    According to the past four quarterly reports, Bluejay diagnostics, inc. (BJDX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.01. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BJDX?

    Bluejay diagnostics, inc. (BJDX)'s Free Cash Flow (FCF) for the period is -1.36M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 29.6% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.